Finally, in one of the studies reviewed, disease flares were reported more frequently in FMF patients on anti-IL1 therapy who had received the mRNA BNT162b2 vaccine than in those on therapy with colchicine alone: 52% vs. 24%, respectively. This evidence concerns the gene IL1B and familial Mediterranean fever.